AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17467137 — intervention group
Group type: EXPERIMENTAL
Intervention: Futurabond NR self-etch adhesive with acid etching of the enamel margin
Number of subjects: 183
Study 17467137 — intervention group
Group type: EXPERIMENTAL
Intervention: Futurabond NR self-etch adhesive with acid etching of the whole cavity for 20s
Number of subjects: 183
Study 17467137 — intervention group
Group type: COMPARATOR
Intervention: Futurabond NR self-etch adhesive without acid etching (control)
Number of subjects: 183
Study 16049639 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanyl-glutamine (0.5 g x kg(‐1) x day(‐1) of undiluted alanyl‐glutamine (20%))
Number of subjects: 20
Study 16049639 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 20
Study 12456429 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40
Study 12456429 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 40
Study 12456429 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane and Desflurane
Number of subjects: 40
Study 10083992 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin puncture (SP) technique
Number of subjects: 82
Study 10083992 — intervention group
Group type: COMPARATOR
Intervention: No skin puncture (NP) technique
Number of subjects: 82
Study 7728369 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (200 mg/day)
Number of subjects: 26
Study 7728369 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden (4 mg/day)
Number of subjects: 26
Study 1674835 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS during treatment and active TENS during stress
Number of subjects: 90
Study 1674835 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS during treatment and placebo TENS during stress
Number of subjects: 90
Study 1674835 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS during treatment and placebo TENS during stress
Number of subjects: 90
Study 1674835 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo TENS during treatment and active TENS during stress
Number of subjects: 90
Study 1674835 — intervention group
Group type: COMPARATOR
Intervention: No treatment during both treatment and stress
Number of subjects: 90
Study 6110504 — intervention group
Group type: EXPERIMENTAL
Intervention: Indenolol 40, 80, 160, and 320 mg
Number of subjects: 16
Study 6110504 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 40, 80, 160, and 320 mg
Number of subjects: 16
Study 6110504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6734921 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil 600 mg/day orally
Number of subjects: 20
Study 6734921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30012120 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental level diet and physical activity intervention targeting obesity
Number of subjects: 10
Study 30012120 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison sites)
Number of subjects: 10
Study 27555505 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP)
Number of subjects: 635
Study 27555505 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 635
Study 27555505 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower education
Number of subjects: 635
Study 27555505 — intervention group
Group type: EXPERIMENTAL
Intervention: Living alone
Number of subjects: 635
Study 27555505 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher weekly alcohol consumption
Number of subjects: 635
Study 27555505 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) among sexually active participants
Number of subjects: 635
Study 27555505 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher depressive symptoms (PHQ-9)
Number of subjects: 635
Study 27555505 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased number of physical comorbidities
Number of subjects: 635
Study 27555505 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic use in participants with chronic kidney disease
Number of subjects: 635
Study 23868103 — intervention group
Group type: EXPERIMENTAL
Intervention: Helplessness/hopelessness
Number of subjects: 1746
Study 23868103 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical workload
Number of subjects: 1746
Study 23868103 — intervention group
Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 1746
Study 22314457 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet nebulizer
Number of subjects: 50
Study 22314457 — intervention group
Group type: COMPARATOR
Intervention: MDI with home-made non-valved spacer (HM NVS)
Number of subjects: 50
Study 20351369 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Number of subjects: 100
Study 20351369 — intervention group
Group type: COMPARATOR
Intervention: Sham laser acupuncture
Number of subjects: 100
Study 18707117 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of collagen hydrolysate (CH) in 100 mL of fermented milk product (FMP)
Number of subjects: 15
Study 18707117 — intervention group
Group type: COMPARATOR
Intervention: 10 g of collagen hydrolysate (CH) dissolved in 100 mL of water (neat hydrolyzed collagen)
Number of subjects: 15
Study 16135577 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance provision of 3 packs of Plan B
Number of subjects: 90
Study 16135577 — intervention group
Group type: COMPARATOR
Intervention: Clinic access (control)
Number of subjects: 90
Study 11570641 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IL-6 monoclonal antibody (1 microg/ml)
Number of subjects: 50
Study 11570641 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IL-10 monoclonal antibody (1 microg/ml)
Number of subjects: 50
Study 11570641 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined anti-IL-6 and anti-IL-10 monoclonal antibodies (each at 1 microg/ml)
Number of subjects: 50
Study 11570641 — intervention group
Group type: COMPARATOR
Intervention: Normal pooled O+ sera
Number of subjects: 50
Study 9559446 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week cardiac rehabilitation intervention
Number of subjects: 201
Study 9559446 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 201
Study 8163319 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise training on a cycle ergometer 3 times a week for 45 min at 75% VO2max
Number of subjects: 19
Study 8163319 — intervention group
Group type: COMPARATOR
Intervention: Sedentary lifestyle (6 weeks)
Number of subjects: 19
Study 3277388 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 282
Study 3277388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study 29748315 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating PCSK9 levels associated with genetic variants (lead SNP rs11591147, PCSK9-R46L)
Number of subjects: 3290
Study 29748315 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating PCSK9 levels
Number of subjects: 3290
Study 29748315 — intervention group
Group type: EXPERIMENTAL
Intervention: PCSK9 gene locus variants
Number of subjects: 3290
Study 29748315 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian Randomization (MR) analysis
Number of subjects: 3290
Study 27151969 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Brief Intervention (EBI) - up to six counselling sessions offered
Number of subjects: 267
Study 27151969 — intervention group
Group type: COMPARATOR
Intervention: Control (usual management including advice on alternative services)
Number of subjects: 267
Study 27151969 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Brief Intervention (EBI)
Number of subjects: 267
Study 24565750 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15mmol/kg contrast agent
Number of subjects: 31
Study 22378583 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 125
Study 22378583 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (50 mg)
Number of subjects: 125
Study 22378583 — intervention group
Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 125
Study 22378583 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (400 mg)
Number of subjects: 125
Study 22378583 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment control
Number of subjects: 125
Study 20798988 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered education program (Group 1)
Number of subjects: 91
Study 20798988 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered education program with additional pharmacist counseling (Group 2)
Number of subjects: 91
Study 20798988 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care only)
Number of subjects: 91
Study 18043787 — intervention group
Group type: EXPERIMENTAL
Intervention: Case conferences
Number of subjects: 461
Study 18043787 — intervention group
Group type: COMPARATOR
Intervention: Routine care by SPCS
Number of subjects: 461
Study 16275525 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary flow velocity (CFV) measured at day 1 after reperfusion
Number of subjects: 29
Study 16275525 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary flow velocity (CFV) measured immediately after reperfusion
Number of subjects: 29
Study 16275525 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor wall-motion recovery group (1-month AWMSI > 2.0, n = 14) CFV at day 1
Number of subjects: 29
Study 12040546 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario 1 (patient in coma, not going to survive ICU)
Number of subjects: 128
Study 12040546 — intervention group
Group type: EXPERIMENTAL
Intervention: Scenario 2 (patient lapsing in and out of consciousness)
Number of subjects: 128
Study 12040546 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of life support withdrawal
Number of subjects: 128
Study 9585279 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (0.2 mg)
Number of subjects: 12
Study 9585279 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (7.5 mg) without epinephrine
Number of subjects: 12
Study 7642863 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmaz-Schatz stent implantation
Number of subjects: 589
Study 7642863 — intervention group
Group type: COMPARATOR
Intervention: Historical balloon angioplasty control series
Number of subjects: 589
Study 2757828 — intervention group
Group type: EXPERIMENTAL
Intervention: tinted lenses
Number of subjects: 24
Study 790410 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0
Study 790410 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study 30561744 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral prophylactic mastectomy (CPM) discussions initiated by patients or providers
Number of subjects: 36
Study 30561744 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient interest in pursuing CPM
Number of subjects: 36
Study 30561744 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider responses to CPM discussions
Number of subjects: 36
Study 30561744 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement levels on CPM discussions
Number of subjects: 36
Study 30903614 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental pain
Number of subjects: 306
Study 30903614 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly household income
Number of subjects: 306
Study 30903614 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental caries
Number of subjects: 306
Study 30122579 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinoprostone vaginal tablets
Number of subjects: 0
Study 30122579 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone slow release retrievable vaginal insert
Number of subjects: 0
Study 27430304 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) combined with anodal transcranial direct current stimulation (a‐tDCS) at 2 mA for 20 minutes, three times per week for 6 weeks
Number of subjects: 42
Study 27430304 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS with PRT
Number of subjects: 42
Study 25037012 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 57
Study 25037012 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival anesthesia
Number of subjects: 57
Study 22057947 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A (600 IU eCG on Day 4 after CIDR insertion)
Number of subjects: 6
Study 22057947 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B (300 IU eCG at the same time)
Number of subjects: 6
Study 22057947 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment C (250 IU FSH on Day 4 post-insertion)
Number of subjects: 6
Study 19155993 — intervention group
Group type: EXPERIMENTAL
Intervention: Aciclovir 400 mg twice daily for 3 months
Number of subjects: 300
Study 19155993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 17228046 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate ketogenic diet (LCKD)
Number of subjects: 119
Study 17228046 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (LFD)
Number of subjects: 119
Study 15744902 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax notoginseng (PNG) 1,350 mg per day for 30 days
Number of subjects: 29
Study 15744902 — intervention group
Group type: COMPARATOR
Intervention: Starch capsule (control) 1,350 mg per day for 30 days
Number of subjects: 29
Study 11991217 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 160 mg/day
Number of subjects: 12
Study 11991217 — intervention group
Group type: COMPARATOR
Intervention: captopril 100 mg/day
Number of subjects: 12
Study 11991217 — intervention group
Group type: EXPERIMENTAL
Intervention: combined therapy (valsartan + captopril)
Number of subjects: 12
Study 9932952 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI demonstrated loss of gray-white matter differentiation and decreased T1- and increased T2-weighted signal in the ipsilateral anterior temporal lobe (AT) in 58% of patients.
Number of subjects: 50
Study 9932952 — intervention group
Group type: COMPARATOR
Intervention: Histologic quantitation showed increased glial cell nuclei counts in intractable TLE cases compared with controls.
Number of subjects: 50
Study 9932952 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence or absence of MRI changes was not predictive of preoperative neuropsychology, postoperative change in neuropsychology, or seizure outcome after surgery.
Number of subjects: 50
Study 7539853 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (8 mg once daily)
Number of subjects: 100
Study 7539853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7539853 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 100
Study 2181787 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenzepine (3 mg in the morning)
Number of subjects: 0
Study 2181787 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (10 mg t.d.s.)
Number of subjects: 0
Study 2181787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2181787 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenzepine and Domperidone
Number of subjects: 0
Study 339141 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg water-soluble bioflavonoids and 600 mg ascorbic acid, administered three times daily
Number of subjects: 50
Study 339141 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg water-soluble bioflavonoids and 1000 mg ascorbic acid, administered five times daily
Number of subjects: 50
Study 339141 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 50
Study 31707972 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n=26)
Number of subjects: 50
Study 31707972 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=24)
Number of subjects: 50
Study 30601059 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Strategies To Enhance Problem‐solving Skills (Positive STEPS) intervention, which includes five individual counseling sessions and daily text message reminders.
Number of subjects: 0
Study 30601059 — intervention group
Group type: COMPARATOR
Intervention: Standard of care control group.
Number of subjects: 0
Study 30601059 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive STEPS intervention
Number of subjects: 0
Study 29267547 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education strategy
Number of subjects: 238
Study 29267547 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit strategy
Number of subjects: 238
Study 29267547 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 238
Study 26370286 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous access using Prostar(™) and Proglide(™) devices
Number of subjects: 0
Study 26370286 — intervention group
Group type: COMPARATOR
Intervention: Surgical cutdown
Number of subjects: 0
Study 26370286 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative nose cultures and perineal cultures
Number of subjects: 0
Study 26370286 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS-scores (Visual analog scale) for patient comfort
Number of subjects: 0
Study 26370286 — intervention group
Group type: EXPERIMENTAL
Intervention: Punch biopsies of the groin
Number of subjects: 0
Study 23791498 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithmic approach of strategies to reverse cerebral desaturation
Number of subjects: 48
Study 23791498 — intervention group
Group type: COMPARATOR
Intervention: No attempts to reverse cerebral desaturation (Control)
Number of subjects: 48
Study 21461953 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Utilities Index 3 (HUI3)
Number of subjects: 0
Study 21461953 — intervention group
Group type: EXPERIMENTAL
Intervention: SF‐6D derived from SF‐36
Number of subjects: 0
Study 21461953 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated Quality of Well‐Being (eQWB)
Number of subjects: 0
Study 19769016 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemplative/preparation group
Number of subjects: 159
Study 17551855 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational counseling (4 sessions of 1.5 hours each)
Number of subjects: 269
Study 17551855 — intervention group
Group type: COMPARATOR
Intervention: Traditional support (4 sessions of 1.5 hours each)
Number of subjects: 269
Study 17551855 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 269
Study 15332021 — intervention group
Group type: EXPERIMENTAL
Intervention: Through-the-scope balloon
Number of subjects: 30
Study 15332021 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-wire balloon
Number of subjects: 30
Study 11498062 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% zinc sulfate nasal spray administered as two inhalations in each nostril four times a day
Number of subjects: 160
Study 11498062 — intervention group
Group type: COMPARATOR
Intervention: Isotonic placebo spray
Number of subjects: 160
Study 10052660 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric Training Group (ETG)
Number of subjects: 10
Study 10052660 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric Training Group (CTG)
Number of subjects: 10
Study 1434088 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐Teboroxime SPECT imaging
Number of subjects: 73
Study 4016543 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentin (1.2g intravenously pre-operatively, with 8 additional doses for gangrenous or perforated appendices)
Number of subjects: 250
Study 4016543 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (500 mg intravenously pre-operatively, with 8 additional doses for gangrenous or perforated appendices)
Number of subjects: 250
Study 4016543 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentin (for gangrenous appendices)
Number of subjects: 250
Study 4016543 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (for gangrenous appendices)
Number of subjects: 250
Study 4016543 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentin (for perforated appendices)
Number of subjects: 250
Study 4016543 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole (for perforated appendices)
Number of subjects: 250
Study 31263017 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback with action implementation toolbox
Number of subjects: 253530
Study 31263017 — intervention group
Group type: COMPARATOR
Intervention: Feedback-only
Number of subjects: 253530
Study 30507899 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT)
Number of subjects: 36
Study 30507899 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy (CPT)
Number of subjects: 36
Study 26385256 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT) for 8 weeks
Number of subjects: 75
Study 26385256 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 75
Study 25404569 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium/formoterol 400/12 μg
Number of subjects: 1925
Study 25404569 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium/formoterol 400/6 μg
Number of subjects: 1925
Study 23091141 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation of 2.5 g/kg LFA
Number of subjects: 624
Study 23091141 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation of 5.0 g/kg LFA
Number of subjects: 624
Study 23091141 — intervention group
Group type: COMPARATOR
Intervention: Control diet (adequate in energy and nutrients)
Number of subjects: 624
Study 19383732 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher haemoglobin (Hb) levels
Number of subjects: 5010
Study 19383732 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaemia incidence after 1 year of follow-up
Number of subjects: 5010
Study 19383732 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in Hb (per SD) at 12 months
Number of subjects: 5010
Study 19383732 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaemia at baseline
Number of subjects: 5010
Study 19383732 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaemia at any time during follow-up
Number of subjects: 5010
Study 17886195 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education (4 x 1.5 hours) and an individual action plan
Number of subjects: 184
Study 17886195 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 184